Dr. Ujjani is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
825 Eastlake Ave E
Seattle, WA 98109Phone+1 206-606-1000- Is this information wrong?
Education & Training
MedStar Health/Georgetown University HospitalFellowship, Hematology and Medical Oncology, 2008 - 2011
University of Pennsylvania Health SystemResidency, Internal Medicine, 2005 - 2008
University of Alabama School of MedicineClass of 2005
Certifications & Licensure
WA State Medical License 2018 - 2025
MT State Medical License 2021 - 2025
DC State Medical License 2008 - 2018
PA State Medical License 2005 - 2008
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2013
Clinical Trials
- Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery Start of enrollment: 2014 May 20
- Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2014 Apr 01
- Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma Start of enrollment: 2017 Mar 01
Publications & Presentations
PubMed
- Hypertension Treatment in Patients Receiving Ibrutinib: A Multicenter Retrospective Study.Laura Samples, Jenna M Voutsinas MPH, Bita Fakhri, Sirin Khajavian, Stephen E Spurgeon, Deborah M Stephens, Alan P Skarbnik, Anthony R Mato, Catherine Broome, Ajay K G...> ;Blood Advances. 2024 Feb 2
- Dual-targeted regimens for the frontline treatment of CLL.Ujjani, C.> ;Hematology. American Society of Hematology. Education Program. 2023 Dec 8
- Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up.Carrie Ho, Ajay K Gopal, Brian G Till, Mazyar Shadman, Ryan C Lynch, Andrew J Cowan, Qian V Wu, Jenna Voutsinas, Heather A Rasmussen, Katherine Blue, Chaitra S Ujjani,...> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Feb 1
- Join now to see all
Journal Articles
- Real World Outcomes and Management Strategies for Venetoclax-Treated Chronic Lymphocytic Leukemia Patients in the United StatesArun K Singavi, Andrew Zelenetz, Nicole Lamanna, Bruce D Cheson, Richard R Furman, Jakub Svoboda, Stephen J Schuster, John N Allan, Chaitra S Ujjani, Haematologica
Abstracts/Posters
- CD20 Targeted CAR-T for High-Risk B-Cell Non-Hodgkin LymphomasChaitra S. Ujjani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Impact of Lab Abnormalities at the Time of Progression in Patients Receiving CD19-Specific CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell LymphomasChaitra S. Ujjani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Veneto-STOP Study: Sequential Assessment of Minimal Residual Disease By Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL...Chaitra S. Ujjani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Press Mentions
The High-Risk Group for Whom Covid-19 Vaccines May Not Work EffectivelyApril 20th, 2021
Axi-Cel Moves Toward the First-Line Setting for High-Risk Large B-cell LymphomaAugust 5th, 2019
Expert Roundtable: Lessons from ASH for Optimizing CLL TreatmentDecember 21st, 2018
Hospital Affiliations
Fred Hutchinson Cancer CenterSeattle, Washington
UW Medicine/University of Washington Medical CenterSeattle, Washington
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
